Gene therapy trial aims to tame rare kidney stone disease
Disease control
Recruiting now
This early-stage study tests a new gene therapy called ABO-101 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The trial will first give a single dose to adults to find the safest amount, then test …
Phase: PHASE1, PHASE2 • Sponsor: Arbor Biotechnologies • Aim: Disease control
Last updated May 04, 2026 02:36 UTC